Unyango olutsha lwe-Liver Fibrosis

I-Sirnaomics Ltd. ibhengeze namhlanje ulawulo lwethamo kwisifundo sokuqala kwiSigaba soku-I solingo lwezonyango lweNkampani ye-siRNA (i-RNA ephazamisayo encinci) yonyango, i-STP707, yonyango lwe-fibrosis yesibindi kwi-primary sclerosing cholangitis kunye nolawulo lwe-intravenous (IV).

I-single-center, i-randomized, i-dose-escalation, i-sequential cohort study ivavanya ukhuseleko, ukunyamezela kunye ne-pharmacokinetics ye-STP707, elawulwa nge-intravenously kumavolontiya anempilo njengedosi enye yokunyuka. Izifundo zihlulwe zibe ngamaqela amane, apho i-Cohort A iya kufumana i-3mg dose nge-IV infusion, i-Cohort B iya kufumana i-6mg, i-Cohort C iya kufumana i-12mg, kunye ne-Cohort D iya kufumana i-24mg. Uphononongo lubhalisa ukuya kutsho kwizifundo ezisempilweni ezingama-50 phakathi kweminyaka eyi-18 ukuya kuma-55 ubudala.

“Olu phando lweSigaba sokuQala linyathelo elibalulekileyo eliya phambili kwinkqubo yethu yophuhliso lwechiza le-fibrosis kwaye liya kusivumela ukuba siqokelele idatha ebaluleke kakhulu kukhuseleko kunye nedosi eya kuxhasa izifundo zethu zexesha elizayo sisebenzisa i-STP707 kunyango lwe-iver fibrosis ngenxa ye-primary sclerosis cholangitis. Olu phononongo luya kusivumela ukuba sandise ukuqonda kwethu ukuba lo mgqatswa wonyango unokuchaphazela njani izigulana ezininzi ezineengxaki ezinqabileyo ezifuna unyango olusebenzayo, "watsho uMlawuli oyiNtloko weSirnaomics kunye neGosa eliyiNtloko lezoNyango uMichael Molyneaux MD.

“Njengolona hlobo luqatha lwe-fibrosis yesibindi, uvavanyo lwe-STP707 kunyango lwe-primary sclerosing cholangitis, luya kuzisa ithemba kwisigulana esikhulu sabantu abahlupheka ngeendlela ezahlukeneyo zesibindi, kunye neemfuno zonyango ezingafezekanga. Lo ngumqondiso obalulekileyo we-Sirnaomics ekuphuhliseni kwethu ukuqulunqwa kwe-IV yale mveliso yonyango ye-siRNA yonyango lwezifo ezingapheliyo, "utshilo uDkt Patrick Lu, uMseki, uSihlalo weBhodi, uMlawuli oyiNtloko, uMongameli kunye ne-CEO ye-Sirnaomics.